Why Shuttle Pharmaceuticals (SHPH) Is Extremely Volatile Today
Why Shuttle Pharmaceuticals (SHPH) Is Extremely Volatile Today
Shuttle Pharma says the company aims to develop drugs that sensitize cancers and protect normal tissues during radiation therapy. Their HDAC inhibitor platform is also being explored for treating autoimmune, inflammatory, metabolic, neurological and infectious diseases.Shuttle Pharmaceuticals Holdings Inc (NASDAQ:SHPH) shares are trading lower by 1.69% to $2.33 Thursday morning, reversing following earlier strength, after the company announced the issuance of U.S. Patent No. 12,077,515, titled "Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease."
升維藥業控股有限公司（納斯達克：SHPH）股價週四上午下跌1.69%，至2.33美元，此前一度上漲，此前公司宣佈發行美國專利號12,077,515，標題爲「選擇性組蛋白去乙酰化酶抑制劑用於人類疾病的治療」。
The stock traded higher by as much as 44% to $3.41 during Thursday's pre-market session.
股票在週四盤前交易中一度上漲44%，至3.41美元。
The patent covers selective histone deacetylase (HDAC) inhibitors designed to regulate genes involved in cancer progression, immune responses, and other biological processes. These inhibitors are being developed for various diseases, including cancer.
該專利覆蓋了選擇性組蛋白去乙酰化酶（HDAC）抑制劑，旨在調節與癌症進展、免疫反應和其他生物過程相關的基因。這些抑制劑正在開發用於治療包括癌症在內的各種疾病。
Shuttle Pharma says the company aims to develop drugs that sensitize cancers and protect normal tissues during radiation therapy. Their HDAC inhibitor platform is also being explored for treating autoimmune, inflammatory, metabolic, neurological and infectious diseases.
升維藥業表示，該公司旨在開發可以在放射治療期間增強癌症敏感性並保護正常組織的藥物。他們的HDAC抑制劑平台還用於研究治療自身免疫性、炎症性、代謝性、神經性和傳染性疾病。
Read Also: Gold Rallies, Yen Surges, Treasury Yields Fall As Disappointing Payrolls Data Supports Large Rate-Cut Bets
閱讀更多：黃金上漲，日元走強，國債收益率下跌，因失望的非農數據支持大幅減息預期。
Is SHPH A Good Stock To Buy?
SHPH是一隻好股票嗎？
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Shuttle Pharmaceuticals's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
投資者在決定一隻股票是否值得購買時可以做出幾個決策。除了估值指標和價格走勢（您可以在例如貝辛格的報價頁面上找到，比如升維藥業的頁面）之外，還有一些因素，比如一家公司是否支付股息或者每個季度是否購買大量股票。
These are known as capital allocation programs. Shuttle Pharmaceuticals does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
這些被稱爲資本配置計劃。升維藥業不支付股息，但顯然有幾種方式可以向股東提供回報。請隨時搜索貝辛格的股息日曆，以尋找下一個即將支付股息的公司，並確定持有該公司股票可以獲得怎樣的收益。
For example, if you're looking to earn an annualized return of 14.14%, you'll need to buy a share of Guggenheim Strategic Opps by the Sep. 13, 2024. Once done, you can expect to receive a nominal payout of $0.18 on Sep. 30, 2024.
舉個例子，如果您想獲得年化回報率14.14％，您需要在2024年9月13日之前買入Guggenheim Strategic Opps的一股。完成後，您可以預計在2024年9月30日收到名義支付$0.18。
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Shuttle Pharmaceuticals will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
回購計劃顯然是不同且高度可變的。公司可以批准回購計劃，並根據批准回購的時間段自行購買股票。瀏覽Shuttle Pharmaceuticals的最新新聞通常可以了解公司是否最近批准了回購計劃。回購計劃通常作爲支持股票價格的力量，爲需求提供背景。
According to data from Benzinga Pro, SHPH has a 52-week high of $6.42 and a 52-week low of $1.28.
根據Benzinga Pro的數據，SHPH的52周最高點爲$6.42，52周最低點爲$1.28。
譯文內容由第三人軟體翻譯。
